MarketPulse

retinal diseases

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026

EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EyePoint Grants Stock Options to New Hires as DURAVYU Phase 3 Trials Advance

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.
EYPTPhase 3 trialsbiopharmaceutical
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

EyePoint Sets March 4 Earnings Call as Pipeline Advances Toward Key Milestones

EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.
EYPTbiopharmaceuticalretinal diseases